Related Experiment Videos
Enisoprost in liver transplantation
Transplantation
|May 15, 1995
Summary
Enisoprost (EP) did not improve renal function or reduce rejection in liver transplant patients. This synthetic prostaglandin analog showed no significant benefits compared to placebo in the study.
Area of Science:
- Nephrology
- Transplantation Immunology
- Pharmacology
Background:
- Prostaglandins may reduce acute rejection and nephrotoxicity in renal transplants.
- Enisoprost (EP) is a synthetic prostaglandin E analog.
Purpose of the Study:
- To evaluate the efficacy of enisoprost (EP) in preventing nephrotoxicity and rejection in orthotopic liver transplantation (OLT).
Main Methods:
- Prospective, randomized, double-blind, placebo-controlled trial.
- 81 adult OLT patients received EP or placebo for 12 weeks post-transplant.
- Renal function (GFR, ERPF) assessed at 4 and 12 weeks.
Main Results:
- No significant differences in creatinine clearance, GFR, or ERPF between EP and placebo groups.
- Incidence of cyclosporine nephrotoxicity (17.5% vs 20.0%) and graft rejection was similar in both groups.
- EP showed no beneficial effect on renal function or rejection rates.
Conclusions:
- Enisoprost, at the studied dosage, does not offer significant benefits for renal function or rejection incidence in OLT recipients.
- Further research may be needed to explore other prostaglandin analogs or dosages.